site stats

Cisplatin target

WebNov 23, 2024 · Cisplatin is the first-line chemotherapy agent for head and neck cancer (HNC), but its therapeutic effects are hampered by its resistance. In this study, we … The compound cis-[Pt(NH3)2Cl2] was first described by Italian chemist Michele Peyrone in 1845, and known for a long time as Peyrone's salt. The structure was deduced by Alfred Werner in 1893. In 1965, Barnett Rosenberg, Van Camp et al. of Michigan State University discovered that electrolysis of platinum electrodes generated a soluble platinum complex which inhibited binary fission in Escherichia coli (E. coli) bacteria. Although bacterial cell growth continued, cell division …

Gene scissors find target for testicular cancer therapy

WebSep 24, 2024 · Cisplatin (CDDP) is the drug of choice against different types of cancer. However, tumor cells can acquire resistance to the damage caused by cisplatin, … WebOct 2, 2024 · Cisplatin is a platinum compound which is widely used in the treatment of various solid tumors including ovarian cancer. Up to now, the mechanism of cisplatin resistance in ovarian cancer is unclear. income tax foc login https://highland-holiday-cottage.com

Potential Cause of Cisplatin-Linked Hearing Loss Identified

WebSep 21, 2016 · PURPOSE: To review the pharmacodynamics, pharmacokinetics, toxicities, and relative clinical activities of cisplatin and carboplatin. Through a search of the MEDLINE database, we identified phase III clinical trials and pharmacologic studies comparing cisplatin and carboplatin published in the English language medical literature … WebOct 23, 2003 · Interestingly, cisplatin also activates CHK2, which is a downstream target of ATM, but the effect of cisplatin on CHK2 appears to be independent of ATM (Damia et al., 2001). WebCisplatin (DDP) is a common therapeutic option for non-small cell lung carcinoma (NSCLC). However, some patients fail to respond to the DDP chemotherapy. Therefore, identifying novel biomarkers to improve the diagnosis and treatment of NSCLC is important. ... Aptamer-targeted nano-zinc carriers were loaded with USP14 siRNA to target DDP ... income tax folio s-f5-c1

Review of the Comparative Pharmacology and Clinical Activity of ...

Category:Reversal of resistance to cisplatin in NSCLC by miRNA-195-5p

Tags:Cisplatin target

Cisplatin target

Cisplatin (NSC 119875) ≥99%(HPLC) - selleckchem

WebWe found that miR-195-5p might play a role as an oncogene in LC cells and have an inhibitory effect on chemotherapy resistance to cisplatin. Afterward, by target gene prediction and confirmation, it was concluded that miR-195-5p might directly target downstream gene FGF2 to affect the resistance to cisplatin and migration invasion … WebCisplatin is a platinum-based chemotherapeutic that has long since been effective against a variety of solid-cancers, substantially improving the five-year survival rates for cancer patients. Its use has also historically been limited by its adverse drug reactions, or cisplatin-induced toxicities (CITs). Of these reactions, cisplatin-induced nephrotoxicity (CIN), …

Cisplatin target

Did you know?

Web2 days ago · Regarding platinum (IV) compounds, the focus was on complexes with biologically active ancillary ligands that exert a synergistic effect with platinum (II)-active complexes upon reduction, or those for which controllable activation can be realized thanks to intracellular stimuli. Web2 days ago · Testicular cancer, also known as testicular germ cell tumors (TGCT), is the most common type of cancer in young men. When treated with cisplatin, the tumor cells …

WebCisplatin (DDP) is a common therapeutic option for non‐small cell lung carcinoma (NSCLC). However, some patients fail to respond to the DDP chemotherapy. Therefore, identifying novel biomarkers to improve the diagnosis and treatment of NSCLC is important. ... Aptamer‐targeted nano‐zinc carriers were loaded with USP14 siRNA to target DDP ... WebWe found that miR-195-5p might play a role as an oncogene in LC cells and have an inhibitory effect on chemotherapy resistance to cisplatin. Afterward, by target gene …

WebNov 29, 2024 · Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment WebJan 10, 2024 · Characterization of cisplatin-loaded chitosan nanoparticles and rituximab-linked surfaces as target-specific injectable nano-formulations for combating cancer Characterization of cisplatin-loaded chitosan nanoparticles and rituximab-linked surfaces as target-specific injectable nano-formulations for combating cancer Authors

WebCisplatin is approved to be used alone or with other drugs to treat: Bladder cancer. It is used alone in patients with advanced cancer that cannot be treated with other therapies, such …

WebJul 28, 2024 · Many of the most commonly prescribed chemotherapeutics, including platinum-based compounds such as cisplatin, target the characteristic genomic instability of tumors by directly damaging the DNA. Chemotherapies are designed to selectively target rapidly dividing cells, where they cause critical DNA damage and subsequent cell death … income tax folio s1-f2-c2 tuition tax creditWebThe drug can be administered to hemodialysis (HD) patients to achieve an AUC of 4–6 such that carboplatin dose (mg)=Target AUCx25. The drug is not avidly protein bound shortly after administration, and approximately 70% is cleared by HD if performed within several hours after in- fusion (15). income tax folio s1-f1-c2WebJul 28, 2024 · Many of the most commonly prescribed chemotherapeutics, including platinum-based compounds such as cisplatin, target the characteristic genomic instability of tumors by directly damaging the … income tax folio s1-f5-c1 pdfWebCisplatin is a chemotherapeutic drug that has been used in the treatment of various types of human cancers such as ovarian, lung, head and neck, testicular and bladder. Cisplatin … income tax folio s1-f3-c4 moving expensesWebOct 31, 2024 · Here, we demonstrate that targeting PAPSS1 in conjunction with cisplatin treatment leads to better response rates in vivo. Clinically, we discovered that low PAPSS1 expression is associated with increased survival rates in chemotherapy-treated NSCLC and ovarian cancer patients. income tax folio s1-f3-c3 support paymentsWeb2 days ago · In addition to genes already known for cisplatin resistance, to our surprise we found the gene NAE1, the regulator of the neddylation cascade," says first author Kai Funke, a Ph.D. student of Prof ... income tax folio s4-f5-c1WebJan 13, 2011 · Cisplatin is one of the most effective chemotherapeutic agents against many forms of cancer including testicular, bladder, head and neck, ovarian, breast, lung, … income tax for 10.5 lakhs